Development of an inhalation unit risk factor for hexavalent chromium

•A new unit risk factor of 2.3E-03 per μgCrVI/m3 has been developed for CrVI.•New dose–response analyses were conducted with the latest scientific methods.•Crump et al. (2003) and Gibb et al. (2000) were utilized for URF development.•Final URF is a combination of the two key URFs weighted by relativ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Regulatory toxicology and pharmacology 2014-03, Vol.68 (2), p.201-211
Hauptverfasser: Haney, Joseph T., Erraguntla, Neeraja, Sielken, Robert L., Valdez-Flores, Ciriaco
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•A new unit risk factor of 2.3E-03 per μgCrVI/m3 has been developed for CrVI.•New dose–response analyses were conducted with the latest scientific methods.•Crump et al. (2003) and Gibb et al. (2000) were utilized for URF development.•Final URF is a combination of the two key URFs weighted by relative confidence. A unit risk factor (URF) was developed for hexavalent chromium (CrVI). The URF is based on excess lung cancer mortality in two key epidemiological studies of chromate production workers. The Crump et al. (2003) study concerns the Painesville, OH worker cohort, while Gibb et al. (2000) regards the Baltimore, MD cohort. A supporting assessment was also performed for a cohort from four low-dose chromate plants (Leverkusen and Uerdingen, Germany, Corpus Christi, TX, Castle Hayne, NC). For the Crump et al. (2003) study, grouped observed and expected number of lung cancer mortalities along with cumulative CrVI exposures were used to obtain the maximum likelihood estimate and asymptotic variance of the slope (β) for the linear multiplicative relative risk model using Poisson regression modeling. For the Gibb et al. (2000) study, Cox proportional hazards modeling was performed with optimal exposure lag and adjusting for the effect of covariates (e.g., smoking) to estimate β values. Life-table analyses were used to develop URFs for each of the two key studies, as well as for supporting and related studies. The two key study URFs were combined using weighting factors relevant to confidence to derive the final URF for CrVI of 2.3E-03 per μgCrVI/m3.
ISSN:0273-2300
1096-0295
DOI:10.1016/j.yrtph.2013.12.005